Expression and significance of MMP-9 and EGFR in epithelial malignant peritoneal mesothelioma

doi:10.3877/cma.j.issn.2095-2015.2017.03.004

Abstract

Abstract:

Objective

To detect the expressions of matrix metalloproteinase(MMP-9)and epidermal growth factor receptor(EGFR)and their relationships with the prognosis in epithelial malignant peritoneal mesothelioma.

Methods

Twenty patients with epithelial malignant peritoneal mesothelioma were selected in Cangzhou Central Hospital from January 2011 to December 2012.The peritoneal tissues were obtained by ultrasound guided puncturing and operation, and were diagnosed by pathology and immunohistochemistry.The expressions of MMP-9 and EGFR in peritoneal tissues were detected by immunohistochemistry(S-P method). The relationships of the expressions of the two markers and age, gender, asbestos exposure were analyzed.All patients were followed up to understand the relationship between markers and prognosis.

Results

In 20 patients with epithelial malignant peritoneal mesothelioma, the positive rates of MMP-9 and EGFR were 75% and 85%, respectively.Multivariate analysis showed that the regression coefficients of age and EGFR were 0.126 0 and 0.774 2, and the P values were 0.007 4 and 0.046, respectively.There was no significant relationship between MMP-9 and patients′ survival time(r=-0.396 1, P=0.114).

Conclusion

In this group of patients, age and EGFR are important factors influencing the survival, but the influences of asbestos exposure, sex and MMP-9 are not related to the survival of patients with epithelial malignant peritoneal mesothelioma.

Key words: Peritoneal neoplasms, Mesothelioma, Matrix metalloproteinase 9, Receptor, Epidermal growth factor, Immunohistochemistry, Prognosis

Yuxin Yang, Yufei Liang, Yonghong Shi, Guoqi Zheng. Expression and significance of MMP-9 and EGFR in epithelial malignant peritoneal mesothelioma[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2017, 07(03): 108-113.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2017.03.004

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2017/V07/I03/108

Figures/Tables 11

References 24

1	Britton M. The epidemiology of mesothelioma[J]. Semin Oncol, 2002, 29(1): 18-25.
2	Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelima: systematic review of clinical management and biological reseach[J]. J Surg Oncol, 2011, 103(8): 822-831.
3	Monteagudo C, Merino MJ, San-Juan J, et al.Immunohisto-chemical distribution of collagenaseⅣinormal, benign and malignant breast tissue[J]. Am J Pathol, 990, 136(3): 585-592.
4	Zhang K, Chen D, Jiao X, et al.Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling[J]. Lab Invest, 2011, 91(3): 426-483.
5	Zeng ZS, Cohen AM, Zhang ZF, et al.Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlats with lymph node and distant metastases[J]. Clin Cancer Res, 1995, 1(8): 899-906.
6	Gaafar R, Bahnassy A, Abdelsalam I, et al.Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma[J]. Lung Cancer, 2010, 70(1): 43-50.
7	Husain AN, Colby T, Ordonez N, et al.Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group[J]. Arch Pathol Lab Med.2013, 137(5): 647-667.
8	Raptopoulos V. Peritoneal mesothelioma[J]. Crit Rev Diagn Imaging, 1985, 24(4): 293-328.
9	魏思忱，郑国启，白文元．恶性腹膜间皮瘤的研究进展[J]．中华消化杂志，2014，34(3)：212-214.
10	宋慧，郑国启，魏思忱，等．以局部炎症为首发症状的恶性腹膜间皮瘤患者的临床特征[J]．中华肿瘤杂志，2014，36(4)：312-313.
11	梁育飞，郑国启，李春英，等．局限性腹膜间皮瘤22例临床分析[J]．中国综合临床，2014，30(9)：953-956.
12	郑国启，张国尊，刘雅刚，等．恶性腹膜问皮瘤1 4例临床分析[J]．中华消化杂志，2014，34(4)：266-269.
13	Yin WJ, Zheng GQ, Chen YF, et al.CT differentiation of malignant peritoneal mesothelioma and tuberculous peritonitis[J]. Radiol Med, 2016, 121(4): 253-260.
14	Yu-Fei L, Guo-Qi Z, Yue-Feng C, et al.CT differentiation of diffuse malignant peritoneal mesothelioma and peritonealcarcinomatosis[J]. J Gastroenterol Hepatol, 2016, 31(4): 709-715.
15	Munkholm-Larsen S, Cao CQ, Yan TD.Malignant peritoneal mesothelioma[J]. World J Gastrointest Surg, 2009, 1(1): 38-48.
16	Busch JM, Kruskal JB, Wu B, et al.Best cases from the AFIP.Malignant peritoneal mesothelioma[J]. Radiographics, 2002, 22(6): 1511-1515.
17	魏思忱，郑国启，王志刚，等．沧州地区162例腹膜恶性间皮瘤临床资料回顾性分析[J]．中华内科杂志，2013，52(7)：599-600.
18	Pillai K, Pourgholami MH, Chua TC, et al.Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma[J]. J Cancer Res Clin Oncol, 2013, 139(6): 117-120.
19	Yu G, Wang J, Chen Y, et al.Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer[J]. Clin Exp Metastasis, 2008, 25(7): 695-702.
20	Setnrliehi MD, Weht Z. How matrix meatlloporetinaseser regulate cell behavior [J]. Annu Rev Cell Dev Biol, 2001, 17: 463-516.
21	Davies B, Miles DW, Happefield LG, et al.Activity of type IV collagenases in benign and malignant breast diease[J]. Br J Cancer, 1993, 67(5): 1126-1131.
22	Mineta H, Borg A, Dictor M, et al.Correlation between p53 mutation neck squamous cell carcinoma cyclin D 1 amplification in neck squamous cell carcinoma[J]. Oral Oncol, 1997, 33(1): 42-46.
23	Enomoto Y, Kasai T, Takeda M, et al.A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma[J]. Pathol Int, 2012, 62(4): 226-231.
24	Rena O, Boldorini LR, Gaudino E, et al.Epidermal growth factor receptor over-expression in malignant pleural mesothlioma: prognostic correlations[J]. J Surg Oncol, 2011, 104(6): 701-705.

表达情况	?	例数	生存时间(月)	P值
MMP-9	＋	15	3.82±1.48	0.040
MMP-9	－	5	8.17±6.43	0.040
EGFR	＋	17	5.89±3.89	0.178
EGFR	－	3	16.00±12.49	0.178

表达情况	?	例数	生存时间(月)	P值
MMP-9	＋	15	3.82±1.48	0.040
MMP-9	－	5	8.17±6.43	0.040
EGFR	＋	17	5.89±3.89	0.178
EGFR	－	3	16.00±12.49	0.178

变量	B	SE	Wald	df	Sig.	Exp(B)	95.0% CI for Exp(B)
变量	B	SE	Wald	df	Sig.	Exp(B)	Lower	Upper
性别	0.2060	1.0842	0.0361	1	0.8493	1.2287	0.1468	10.2872
年龄	0.1260	0.0470	7.1819	1	0.0074	1.1343	1.0344	1.2438
MMP-9	－0.3961	0.2481	2.5481	1	0.1104	0.6730	0.4138	1.0944
EGFR	0.7742	0.3888	3.9646	1	0.0465	2.1688	1.0122	4.6469
石棉接触	0.3747	1.0047	0.1391	1	0.7092	1.4545	0.2030	10.4214

变量	B	SE	Wald	df	Sig.	Exp(B)	95.0% CI for Exp(B)
变量	B	SE	Wald	df	Sig.	Exp(B)	Lower	Upper
性别	0.2060	1.0842	0.0361	1	0.8493	1.2287	0.1468	10.2872
年龄	0.1260	0.0470	7.1819	1	0.0074	1.1343	1.0344	1.2438
MMP-9	－0.3961	0.2481	2.5481	1	0.1104	0.6730	0.4138	1.0944
EGFR	0.7742	0.3888	3.9646	1	0.0465	2.1688	1.0122	4.6469
石棉接触	0.3747	1.0047	0.1391	1	0.7092	1.4545	0.2030	10.4214

临床资料		例(%)	生存时间(月)	P值
性别		?	?	?
?	女	17(85)	7.65±6.42	0.647
?	男	3(15)	9.33±6.24	0.647
年龄		?	?	?
?	>55岁	15(75)	5.86±4.71	0.000
?	<55岁	5(25)	12.0±8.71	0.000
石棉接触		?	?	?
?	＋	13(65)	5.0±2.41	0.029
?	－	7(35)	11.85±8.87	0.029

Please choose a citation manager

Content to export